USPTO serial 90226491
RADX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 26, 2021
- Examiner
- BAKER, JORDAN A
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with RADX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,300
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
U.S. Department of Health and Human Services
Bethesda, MD, US
Other trademarks owned by U.S. Department of Health and Human Services
U.S. Department of Health and Human Services
Bethesda, MD, US
Other trademarks owned by U.S. Department of Health and Human Services
U.S. Department of Health and Human Services
Bethesda, MD, US
Other trademarks owned by U.S. Department of Health and Human Services
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Angela Y. Dai
Angela Y. Dai OFFICE OF THE GENERAL COUNSEL31 CENTER DRIVEBLDG. 31, SUITE 2B-50BETHESDA, MD 20892Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Promoting research, development, validation, commercialization, and implementation of testing technologies for pathogens; promoting research, development, validation, commercialization, and implementation of testing technologies for viruses; promoting research, development, validation, commercialization, and implementation of testing technologies for viruses that cause COVID-19 and influenza flu; promoting improvement of clinical laboratory testing technologies for COVID-19 and influenza flu; promoting research, development, validation, commercialization, and implementation of testing technologies for pathogens through support of scientific organizations, research institutions, medical institutions, academic institutions, non-profit organizations, and business entities; promoting research, development, validation, commercialization, and implementation of testing technologies for viruses that cause COVID-19 and influenza flu through support of scientific organizations, research institutions, medical institutions, academic institutions, non-profit organizations, and business entities; promoting collaboration within the scientific, research, medical, academic, and business communities to advance research, development, commercialization, and implementation of testing technologies for pathogens; promoting collaboration within the scientific, research, medical, academic, and business communities to advance research, development, commercialization, and implementation of testing technologies for viruses that cause COVID-19 and influenza flu; promoting collaboration within the technology innovator, clinical testing, regulatory affairs, entrepreneur, business leader, and community leader networks to advance research, development, commercialization, and implementation of testing technologies for pathogens; promoting collaboration within the technology innovator, clinical testing, regulatory affairs, entrepreneur, business leader, and community leader networks to advance research, development, commercialization, and implementation of testing technologies for viruses that cause COVID-19 and influenza flu; promoting community-engaged projects to assess and expand availability of testing technologies for pathogens in underserved and/or vulnerable populations; promoting community-engaged projects to assess and expand availability of testing technologies for viruses that cause COVID-19 and influenza flu in underserved and/or vulnerable populations; promoting collaboration between the scientific research community and underserved and/or vulnerable populations to achieve increased accessibility and availability of testing technologies for pathogens in underserved and/or vulnerable populations; promoting collaboration between the scientific research community and underserved and/or vulnerable populations to achieve increased accessibility and availability of testing technologies for viruses that cause COVID-19 and influenza flu in underserved and/or vulnerable populations; promoting rapid scale-up of testing technologies for pathogens; promoting rapid scale-up of testing technologies for viruses that cause COVID-19 and influenza flu; promoting increased availability of testing technologies for pathogens; promoting increased availability of testing technologies for viruses that cause COVID-19 and influenza flu; administration and management of research grants; administration of programs for promoting research, development, validation, commercialization, and implementation of testing technologies for pathogens; administration of programs for promoting research, development, validation, commercialization, and implementation of testing technologies for viruses that cause COVID-19 and influenza flu | ACTIVE | Apr 29, 2020 |
| 036 | Providing grants and financial support for biomedical research and development; providing grants and financial support for biomedical engineering; providing grants and financial support for research, development, validation, commercialization, and implementation of testing technologies for pathogens; providing grants and financial support for research, development, validation, commercialization, and implementation of testing technologies for viruses; providing grants and financial support for research, development, validation, commercialization, and implementation of testing technologies for viruses that cause COVID-19 and influenza flu; providing grants and financial support for community-engaged projects, namely, establishment of clinical research sites and testing centers in underserved and/or vulnerable communities; providing information regarding funding opportunities relating to biomedical and scientific research and developments via a website | ACTIVE | — |
| 041 | Providing a website featuring blogs, non-downloadable videos, non-downloadable videocasts, and educational presentations in the nature of seminars, forums, and non-downloadable webinars relating to medical, biomedical and scientific research information and distribution of educational materials in connection therewith | ACTIVE | — |
| 042 | Providing a website featuring medical, biomedical and scientific research information; providing a website featuring news in the field of biomedical and scientific research and developments; providing a website featuring biomedical and scientific research information and developments, namely, dashboards displaying biomedical and scientific research data, information and developments | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by U.S. Department of Health and Human Services
- Other trademarks owned by U.S. Department of Health and Human Services
- Other trademarks owned by U.S. Department of Health and Human Services
- Other trademarks in Class 035
- Other trademarks in Class 036
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named RADX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 26, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 10, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 10, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 21, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 8, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 21, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 21, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 21, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 25, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 21, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 18, 2020 | PCGR | PETITION TO DIRECTOR GRANTED | — |
| Dec 17, 2020 | APET | ASSIGNED TO PETITION STAFF | — |
| Nov 16, 2020 | TPDR | TEAS PETITION TO DIRECTOR RECEIVED | — |
| Nov 14, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 3, 2020 | NWAP | NEW APPLICATION ENTERED | — |